ELEVATION ONCOLOGY INC (ELEV)
US28623U1016 - Common Stock
Overall ELEV gets a fundamental rating of 2 out of 10. We evaluated ELEV against 564 industry peers in the Biotechnology industry. While ELEV seems to be doing ok healthwise, there are quite some concerns on its profitability. ELEV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ELEV had negative earnings in the past year.
ELEV had a negative operating cash flow in the past year.
In the past 5 years ELEV always reported negative net income.
ELEV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -34.65%, ELEV is in the better half of the industry, outperforming 62.92% of the companies in the same industry.
ELEV has a better Return On Equity (-49.07%) than 66.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.65% | ||
| ROE | -49.07% | ||
| ROIC | N/A |
ROA(3y)-57.89%
ROA(5y)-100.9%
ROE(3y)-100.07%
ROE(5y)-155.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ELEV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ELEV has more shares outstanding
ELEV has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.07, we must say that ELEV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.07, ELEV is in line with its industry, outperforming 51.16% of the companies in the same industry.
ELEV has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
ELEV's Debt to Equity ratio of 0.38 is on the low side compared to the rest of the industry. ELEV is outperformed by 71.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.07 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ELEV has a Current Ratio of 41.10. This indicates that ELEV is financially healthy and has no problem in meeting its short term obligations.
ELEV's Current ratio of 41.10 is amongst the best of the industry. ELEV outperforms 98.93% of its industry peers.
A Quick Ratio of 41.10 indicates that ELEV has no problem at all paying its short term obligations.
ELEV has a Quick ratio of 41.10. This is amongst the best in the industry. ELEV outperforms 98.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 41.1 | ||
| Quick Ratio | 41.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 76.26% over the past year.
EPS 1Y (TTM)76.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 10.76% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y45.19%
EPS Next 2Y18.9%
EPS Next 3Y8.82%
EPS Next 5Y10.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ELEV. In the last year negative earnings were reported.
Also next year ELEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.9%
EPS Next 3Y8.82%
5. Dividend
5.1 Amount
ELEV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ELEVATION ONCOLOGY INC
NASDAQ:ELEV (11/4/2024, 8:05:07 PM)
After market: 0.538 +0.02 (+2.95%)0.5226
-0.01 (-2.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap30.89M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.65% | ||
| ROE | -49.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 41.1 | ||
| Quick Ratio | 41.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)76.26%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y45.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y